PATENT CLAIM ANALYSIS

Application Number: 15937594
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "223200"]

Abstract:
Provided are immediate or prolonged administration of certain potassium ATP (K ATP ) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP  channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K ATP  channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering K ATP  channel openers with other drugs to treat diseases of humans and animals.

Claim (Index 26):
The method of  claim 24 , wherein the tricyclic antidepressant is selected from the group consisting of doxepin, clomipramine, amitriptyline, maproiline, desipromine, nortryptyline, desipramine, doxepin, trimipramine, imipramine and protryptyline.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.63333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14458032', '12391990', '14940018', '15195826', '15671792']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8353082303476457
- 35 USC 102 Novelty (BERT): 0.5842604198736512
- Combined Prediction Score: 0.8102034493002462
- Mean Citation Score: 369.046582
- Max Citation Score: 374.8041
- Similarity Product: 231.00949990911485

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test